The Filing Desk

Tactile Systems Technology

TCMD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

TCMD · Last close · November 13, 2026
$26.81
Value Tactile Systems Technology yourself

Tactile Systems Technology's revenue rose 12.5% to $330 million in fiscal 2025. Its operating margin was 8.9%, up from 7.6% a year earlier. Free cash flow was $40 million, up 5.7%. It paid out $27 million in dividends and buybacks, 66% of free cash flow. The diluted share count fell 3.5%.

Tactile Systems Technology, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 17, 2026 · 0001104659-26-016380 Updated
Revenue
$330M
12.5%
Operating margin
8.9%
1.3 pts
Net income
$19M
12.5%
Free cash flow
$40M
5.7%
Return on capital
12.6%
2.2 pts
Market cap
$617M
Nov 13 close
P/E
26.0x
On $1.03 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Tactile Systems Technology does

Tactile Systems Technology, which does business as Tactile Medical, makes medical devices that people use at home to treat long-term conditions. Its focus is vascular disease, mainly lymphedema (chronic swelling when the lymph system can't drain fluid) and chronic venous insufficiency, cancer-related lymphedema, and airway clearance for people with chronic lung conditions.

It sells in two ways. For its lymphedema products it deals directly with patients and clinicians: it gets referrals, handles insurance claims, delivers the device and trains the patient. For its AffloVest airway clearance product it sells to accredited durable medical equipment providers, who handle the payer paperwork and patient support.

In 2025 it had revenue of $329.5 million and net income of $19.1 million. Revenue rose 12% from 2024. It says most of its revenue comes from lymphedema products, and that Medicare and other insurers' coverage rules matter greatly to its sales.

Its biggest risks, as it describes them

  • Changes in Medicare coverage rules, or insurers' reimbursement, could hurt sales of its products.
  • Its revenue comes mainly from lymphedema products, so it is highly dependent on them.
  • It must expand and manage its direct sales teams and its relationships with distributors.
  • It buys some parts from single-source suppliers, and losing one could disrupt production.
  • Doctors and insurers may demand more clinical studies before prescribing or covering its products.
From Tactile Systems Technology's annual report on Form 10-K, filed February 17, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 20.8% a year and net income 23.3% a year, as new shares raised the share count by 116% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2822619483
Debt incl. finance leases302429260
Net debt (negative means net cash)22−32−68−83
Net debt to EBITDA0.9x—−1.3x−2.4x−2.3x
Debt to equity0.2x0.2x0.1x0.1x0.0x
Interest coverage−13.6x−4.6x4.3x10.6x28.2x
Current ratio3.3x1.9x3.5x4.4x4.0x
Quick ratio2.7x1.5x3.0x3.9x3.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Tactile Systems Technology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Tactile Systems Technology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 96 of 98 of 9
Rule of 4023.4%19.8%24.7%
Altman Z''5.406.708.52
Accruals ratio−2.7%−8.2%−8.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio rosePassPassFail
Share count didn't riseFailFailPass
Gross margin roseFailPassPass
Revenue rose relative to assetsPassFailPass
F-score6 of 96 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Tactile Systems Technology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Tactile Systems TechnologyFY2512.5%8.9%12.3%12.6%−2.3x8
AngiodynamicsFY269.5%−12.5%0.2%−24.6%—4Compare
PROCEPT BioRoboticsFY2537.2%−33.7%−18.9%−65.4%—5Compare
LeMaitre VascularFY2513.5%27.2%29.8%25.5%−2.4x5Compare
ArtivionFY2513.6%7.7%0.2%3.9%2.7x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue84109144190187208247274293330
Revenue growth34.5%29.3%31.5%31.8%−1.2%11.2%18.6%11.2%6.8%12.5%
Gross profit6280102134133148176195217250
Research and development4555567898
Operating income44310−4−2−13182229
Net income36711−1−12−18281719
Diluted EPS (US$)0.150.310.340.56−0.03−0.60−0.891.230.700.82
Diluted shares (millions)11191920192020232423
Cash flow
Cash from operations7492335364143
Capital expenditure1445222222
Free cash flow605−3113343840
Dividends paid0000000000
Share buybacks00000000427
Acquisitions0000000000
Stock-based compensation24810111010888
Balance sheet at fiscal year end
Cash and short-term investments42444645482822619483
Debt incl. finance leases—————302429260
Total assets7488107152174244255281298274
Total liabilities1416183949116134888155
Shareholders' equity607389113125128121194217219
Margins and ratios
Gross margin72.9%73.5%71.1%70.8%71.0%71.2%71.3%71.1%74.0%75.9%
Operating margin5.0%3.6%2.1%5.5%−1.9%−0.8%−5.2%6.6%7.6%8.9%
Net margin3.4%5.4%4.6%5.8%−0.3%−5.7%−7.2%10.4%5.8%5.8%
Free cash flow margin7.4%0.4%3.4%−1.6%0.4%0.2%1.4%12.2%13.1%12.3%
Rule of 40 (growth + FCF margin)41.9%29.7%34.9%30.3%−0.8%11.4%20.0%23.4%19.8%24.7%
Return on capital——————−8.0%12.7%10.3%12.6%
Return on equity10.7%8.8%8.2%10.9%−0.5%−9.3%−14.3%18.1%8.3%8.8%
Return on assets5.2%7.2%6.8%8.5%−0.4%−5.7%−7.2%10.6%5.8%6.7%
Net debt to EBITDA—————0.9x—−1.3x−2.4x−2.3x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Tactile Systems Technology's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Tactile Systems Technology.